Solid Biosciences advances gene therapies for muscular and cardiac diseases, gaining FDA clearance for SGT-212 and targeting ...

Truist launched its coverage of gene therapy developer Solid Biosciences (NASDAQ:SLDB) on Wednesday with a Buy recommendation and a $16 per share target, citing an attractive valuation setup ahead of ...

A live webcast of the presentation will be available on the Events page of the Investors section of the Company website or by clicking here. A webcast replay will be archived for 30 days on the Events ...

Current major projects in the lab focus on the molecular basis of inherited arrhythmia syndromes like catecholaminergic polymorphic ventricular tachycardia (CPVT), congenital long QT syndrome (LQTS), ...